Compare The Vita Coco Company Inc (COCO) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
The Vita Coco Company Inc vs GSK plc — how do they compare? The Vita Coco Company Inc trades at $74.45 (market cap $4.23B), while GSK plc trades at $51.21 (market cap $101.55B). The key difference: GSK plc is far larger — about 24× The Vita Coco Company Inc's market cap, and GSK plc pays a 3.5% dividend while The Vita Coco Company Inc pays none. Which is the better fit depends on your goals.
| COCO | GSK | |
|---|---|---|
Market Cap | $4.23B | $101.55B |
Sector | Technology | Health |
52-Week High | $84.02 | $61.18 |
52-Week Low | $32.30 | $36.20 |
Enterprise Value | $4.04B | $122.16B |
Dividend Yield | — | 3.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
COCO trades at $74.635, up 4.53% today, with a bullish technical signal and strong earnings momentum after beating Q1 2026 EPS estimates. The company reported 37% YoY revenue growth in Q1 2026, with management raising full-year guidance. Analysts maintain a $78.00 consensus price target, with 60% recommending Buy. Key support lies at $72, with resistance at $76.
Outlook remains positive driven by international expansion and dominant market position, but elevated valuation multiples pose risks. Upside depends on sustained execution against raised guidance, while any earnings miss or margin pressure could trigger volatility. The stock offers growth exposure but requires monitoring of competitive and consumer spending trends.
GSK trades at $52.29, down 0.93% with neutral technical signals. The company shows strong fundamentals with Q1 2026 EPS beating expectations at $1.24 versus $1.16 forecast. Recent FDA approvals for Utebzi and positive Jemperli trial results highlight pipeline strength. Valuation metrics appear reasonable with P/E of 13.94 and ROE of 36.42%.
GSK presents a balanced investment case with solid profitability and promising drug pipeline offset by mixed analyst sentiment and competitive pressures. The stock offers income potential with 3.46% dividend yield but faces execution risks in drug development and market competition.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About The Vita Coco Company Inc
The Vita Coco Company is a leading functional beverage brand specializing in coconut water. Its portfolio includes its flagship Vita Coco brand, clean energy drinks, and sustainable enhanced water products.
Read more on COCO →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
